诱导多能干细胞衍生的心肌细胞:从监管地位到临床翻译
Catarina S P Soares1, Maria H L Ribeiro1,2,3
1Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.
Tissue engineering. Part B, Reviews
|December 27, 2023
概括
干细胞疗法对心血管疾病有希望,但在安全有效地制造诱导多能干细胞 (iPSCs) 方面仍然存在挑战. 需要进一步的规定,以确保患者使用的iPSC衍生心肌细胞产品的质量和安全.
科学领域:
- 心血管医学 心血管医学
- 再生医学是一种再生医学.
- 干细胞生物学 干细胞生物学
背景情况:
- 心血管疾病是全球主要的死亡原因,再生疗法有限.
- 干细胞疗法,特别是诱导多能干细胞 (iPSP),为心肌细胞再生提供了潜力.
- 目前的大规模iPSC生产缺乏标准化的良好制造实践 (GMP) 准则,造成质量风险.
研究的目的:
- 为了确定iPSC衍生心肌细胞 (iPSC-CMs) 的关键质量属性 (CQAs).
- 确保监管合规和心血管治疗开发中的患者安全.
- 审查来自EMA,FDA和PMDA的现有立法和监管指南.
主要方法:
- 对iPSCs和iPSC-CM疗法的文献综述.
- 分析主要卫生机构 (EMA,FDA,PMDA) 的监管指南.
- 确定关键的质量属性和监管缺口.
主要成果:
- 缺乏标准化GMP用于大规模的iPSC生产.
- iPSC产品中的潜在质量风险可能会危及患者的安全.
- 需要加强对iPSC-CM分化,成熟和瘤性监测的法规.
结论:
- 为了监测iPSC-CM的发展,额外的法规和准则是必不可少的.
- 符合GMP的细胞库和快速审批系统可以改善患者的接入.
- 标准化的CQA对于安全有效的iPSC-CM心血管疗法至关重要.
更多相关视频
相关概念视频
Induced Pluripotent Stem Cells
23.2K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
23.2K
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K


